Newest
-
MEXC COO Vugar Usi on Navigating Crypto's 2026 Reset: Why Retail-First Exchanges Are Winning
-
CYCJET high-resolution inkjet printers – the "surgical scalpel" for the Russian packaging industry.
-
2026 Zhongshenghui · Buddhist Faith and Collective Practice Exchange Forum in the Digital Age Successfully Held in Bangkok, Thailand
-
From packaging to production lines: How CO2 laser marking machines are reshaping environmental and efficiency standards for product identification.
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
2025-02-14
DAAN Biotherapeutics
HaiPress
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."